Veradermics, Inc (MANE) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$109.30

From 52W high−17.72%

Volume1.87M

Market cap$4.46B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$109.30

From 52W high

−17.72%

Volume

1.87M

Market cap

$4.46B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−37.4x

P/E (TTM)

—

RSI (14)

51.7

MomentumView details →

1D Return

−1.78%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−37.4x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

5.5x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−11.39%

ROA (TTM)

−11.22%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

−1.78%

YTD Return

—

1Y Return

—

RSI (14)

51.7

vs 50D SMA

−1.65%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

70.53x

Quick Ratio

70.53x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.58

EPS Surprise

10.43%

Beats (12Q)

1/12

Next Q EPS Est

−$0.61

Avg Surprise (4Q)

10.43%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−92.68M

Op. CF (TTM)

−78.30M

Next earningsNov 10, 2026 →

Latest newsMore news →

Veradermics reported its financial results for the second quarter ended June 30, 2026.40d ago

Veradermics Incorporated released topline results from an open-label Phase 2 trial of its experimental oral hair loss drug VDPHL01 in women with mild-to-moderate pattern hair loss.67d ago

Similar companies

Amicus Therapeutics, Inc.FOLD 丰倍生物603334.SH Adaptive Biotechnologies CorporationADPT Jacobio Pharmaceuticals Group Co., Ltd.01167.HK Iovance Biotherapeutics, Inc.IOVA Telix Pharmaceuticals LimitedTLX Find similar companies →

Latest newsMore news →

Veradermics reported its financial results for the second quarter ended June 30, 2026.40d ago Veradermics Incorporated released topline results from an open-label Phase 2 trial of its experimental oral hair loss drug VDPHL01 in women with mild-to-moderate pattern hair loss.67d ago